Information
More articles below:
Study Shows Some Anti-Seizure Meds Raise Suicide Risk
Survey May Help Docs Diagnose Mood Disorders
Antipsychotics Still Widely Used in U.S. Nursing Homes
Lithium Beats Valproate for Long-Term Bipolar Therapy
Antidepressants May Change Your Personality
Bipolar Disorder May Be Tied to Body Clock
Risperdal Consta Approved for Bipolar Disorder
MONDAY, May 18 (HealthDay News) -- The Janssen Pharmaceuticals drug Risperdal Consta (risperidone) has been approved by the U.S. Food and Drug Administration for people with Bipolar 1 disorder, the drug maker said Monday.
Risperdal Consta is the long-acting version of Risperdal, which was first FDA-approved more than a decade ago and is now sanctioned for Bipolar 1, schizophrenia and autism.
Type 1 bipolar disorder involves at least one manic episode, with or without a major depressive episode.
Approval of Risperdal Consta for Bipolar 1 was granted as a single therapy, or in combination with lithium or valproate, Janssen said in a news release.
As with similar antipsychotic drugs, the packaging for Risperdal Consta includes a warning that the drug is not approved for elderly people with dementia-related psychosis, and could increase their risk of death.
More information
The FDA has more about this drug's approval history.
DON'T HAVE Rx COVERAGE?Click Here to print out your FREE OPTIMIZERx Card and instantly begin savings on your next prescriptions!
